Skip to main content Skip to search Skip to main navigation

How do we deal with risks?

Whether in the professional or private environment – risks accompany us in all situations in life. Dealing with these risks is generally based on knowledge and experience. A methodical approach transforms the individualised handling of risks into structured risk management. On the other hand, disadvantages for the individual, the company and patient protection outweigh the risks in situations where risks are dismissed as a trivial matter or ignored.

[GMP Compliance Adviser, 19.A]


 

Would you like to discover more?

The GMP Compliance Adviser is the world's largest knowledge portal for quality management in the pharma business. 

The demo access is non-binding and ends automatically.

Test it now for free

You may also be interested in the following articles:

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

EU: First Four EUDAMED Modules Mandatory from 28 May 2026

With Commission Decision (EU) 2025/2371, the European Commission has formally declared that the first four EUDAMED modules meet the required functional specifications. Publication in the OJEU on 27 November 2025 activates the six-month transition period foreseen in Regulation (EU) 2024/1860.

Read more
Swissmedic: Digital Package Leaflet Instead of Paper

Swissmedic: Digital Package Leaflet Instead of Paper

From 1 December 2025, medicines intended solely for use by healthcare professionals no longer require a printed package leaflet. Instead, a QR code on the outer packaging must provide direct access to the professional information.

Read more
EMA: 6 New Nitrosamines for Appendix 1

EMA: 6 New Nitrosamines for Appendix 1

Appendix 1 of EMA’s Questions and Answers on nitrosamine impurities has been updated. This appendix contains acceptable intakes (AIs) established for N-nitrosamines.

Read more
Previous
Next